Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

The price of knowledge

About the author: 

The pharmaceutical industry argues that it would cost too much to be more open about the potential dangers of its products

The pharmaceutical industry argues that it would cost too much to be more open about the potential dangers of its products.

The UK Medicines Control Agency, which licences new drugs, is funded entirely by applications from the drug companies. It is the only drugs agency in the EC which depends on the potential licensee so completely.The drugs industry has made it clear that it is not prepared to see the licensing costs increase so that the public can have greater access to information. As it pays the piper, so it it can call the tune.

Nonetheless, Charles Medawar of Social Audit says that for every lb1 drug companies spend on providing information on drugs, they spend a further lb40 on marketing the product. Professor Bill Inman, former head of the Drug Safety Research Unit, estimates that lb1m can be added to the drug's launch costs through post marketing studies without increasing knowledge about its safety or efficacy, so poor and sales oriented are the trials.

But the Campaign for Freedom of Information, co-sponsor of the blocked Medicines Information Bill, says the costs argument is a red herring. Additional costs if the bill had gone through would have been minimal, it argues.

The dilemma highlights the problem of the dual role played by the MCA. On the one hand, it must ensure safe medicines come to the market, while on the other providing a service to the drugs companies.

The argument could be quickly resolved by the government if it was truly committed to openness, simply by underwriting the initial costs of the MCA.


Short takes

For love of helenor

You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved